Researchers at the University of Florida and Trinity College Dublin have identified the gene SLC35F2 as the long-sought molecular gateway that imports the micronutrient queuine into human cells, closing a search that lasted more than three decades. Queuine is a small molecule sourced entirely from diet or gut bacteria, and its modified form, queuosine, is chemically attached to transfer RNA, the machinery cells use to build proteins. The discovery directly connects a single transporter protein to both brain protection and cancer defense, reframing a gene once studied mainly as a drug-entry route into a normal-physiology nutrient channel with broad medical implications.
Why a 30-year transporter hunt matters for patients
Human cells cannot manufacture queuine on their own. They depend on bacteria in the gut or on food to supply it, making queuine functionally similar to a vitamin. Once inside a cell, queuine is swapped onto specific transfer RNAs by an enzyme complex, and the resulting queuosine modification influences how accurately proteins are assembled. Scientists recognized this dependency decades ago, yet the identity of the protein that actually pulls queuine across the cell membrane remained unknown. That gap left researchers unable to test whether blocking or boosting queuine uptake could slow tumor growth or shield neurons from degeneration.
The new finding changes that equation. According to a study in PNAS, gene knockout and uptake assays demonstrated that cells lacking SLC35F2 fail to incorporate queuosine into their tRNA. When SLC35F2 was restored, queuine uptake and tRNA modification returned, strongly implicating this transporter as the critical entry point. With the transporter now named, drug designers and nutritional scientists have a concrete target rather than a theoretical one.
One reason the result carries weight beyond basic biology is the difference between cancer cells and neurons. Tumors divide rapidly and constantly turn over their tRNA pools, meaning they need a steady fresh supply of queuine to maintain queuosine-modified tRNA. Neurons, by contrast, are post-mitotic: they rarely divide and can rely on stable, already-modified tRNA for extended periods. A targeted inhibitor of SLC35F2 could, in principle, starve fast-dividing cancer cells of queuosine while leaving neurons largely unaffected, because neurons would draw on their existing reserves rather than depending on continuous import. No clinical trial has tested this idea yet, but the identification of SLC35F2 makes such experiments feasible for the first time.
That prospect is especially intriguing in light of prior work linking queuine to neuroprotection. Animal and cellular models summarized in a review of queuosine biology suggest that adequate queuine levels support mitochondrial function and reduce oxidative stress, processes that are central to many neurodegenerative diseases. The same biochemical pathways that help neurons withstand damage may also influence how cancer cells respond to metabolic stress, placing SLC35F2 at a critical crossroads between brain health and tumor vulnerability.
How SLC35F2 was identified and what earlier work missed
The gene SLC35F2, formally cataloged as solute carrier family 35 member F2 in Homo sapiens, was already known to cancer pharmacologists. Earlier research characterized it as a high-specificity transporter for YM155, a clinically evaluated anticancer compound that causes DNA damage in tumor cells. That work, published in Nature Chemical Biology, showed that cells expressing high levels of SLC35F2 were especially sensitive to YM155 because the transporter efficiently shuttled the drug inside.
The new finding reinterprets that earlier picture. Rather than existing primarily to let drugs in, SLC35F2 appears to serve a normal physiological role: importing the micronutrient queuine from dietary and microbial sources. YM155 sensitivity, in this revised view, was a side effect of the transporter’s natural affinity for small molecules shaped like queuine. The two findings are not contradictory, but they do create a tension that future studies will need to resolve. If SLC35F2 handles both queuine and YM155, drug developers will have to account for competition between the nutrient and the therapeutic agent at the same binding site.
Separate research on microbiome-derived metabolites has added another layer. A study in Nature Cell Biology found that two microbial metabolites compete for the same tRNA modification pathway, and it explicitly referenced SLC35F2 as the transporter responsible for queuine uptake. That independent confirmation from a different research group strengthens the case that SLC35F2 is not merely one of several possible importers but the primary gate. It also connects queuine biology directly to the composition of the gut microbiome, implying that shifts in microbial communities could influence SLC35F2-mediated flux into host tissues.
For the University of Florida team, the transporter discovery capped years of work on how queuine moves from the gut into the brain. In a university news release, the investigators described SLC35F2 as a “missing link” that explains how a molecule made by bacteria can end up modifying tRNA in neurons. That framing underscores a broader shift in thinking: nutrients produced by microbes are increasingly seen not just as peripheral metabolites but as integral components of human cellular machinery.
From microbiome to medicine
The queuine story sits at the intersection of nutrition, microbiology and oncology. Because humans cannot synthesize queuine, they rely entirely on external sources. Gut bacteria produce it as part of their own RNA metabolism, and queuine or its precursors are also present in certain foods. Once liberated in the intestinal lumen, queuine must traverse several barriers-intestinal epithelium, bloodstream and finally cell membranes-before it can be attached to tRNA in distant organs.
By pinning queuine’s cellular entry on SLC35F2, the new work suggests several concrete intervention points. One is diet: if specific foods or probiotic strains reliably boost systemic queuine levels, they might enhance queuosine modification in tissues where SLC35F2 is abundant. Another is pharmacology: small molecules that modestly increase SLC35F2 activity could, in theory, raise intracellular queuine in vulnerable neurons, while carefully tuned inhibitors could deprive tumors of a modification they rely on for efficient protein synthesis.
However, those ideas remain speculative without quantitative data. It is not yet clear how much queuine intake is needed to saturate SLC35F2, or how rapidly tissues deplete their queuosine-modified tRNA under stress. Nor is it known whether chronic high queuine exposure has downsides, such as inadvertently supporting the growth of certain cancer cells that exploit queuosine for survival. These uncertainties argue for cautious, mechanism-driven development rather than broad supplementation.
Gaps in the evidence and what to watch next
Several important questions remain open. No published dataset yet compares SLC35F2 expression levels in human brain tissue against expression in common tumor types at single-cell resolution. Without that map, the hypothesis that neurons can tolerate SLC35F2 inhibition better than cancer cells stays logical but unproven. Similarly, no population-level data exist on how queuine concentrations vary across diets or microbiome compositions, so the nutritional side of the story lacks quantitative grounding.
Longitudinal clinical records linking natural variants in the SLC35F2 gene to neurological outcomes or cancer incidence have not been reported in the available literature. Such genetic epidemiology studies would help determine whether people with reduced SLC35F2 function face higher rates of neurodegeneration or, conversely, lower rates of certain cancers. Until those analyses appear, the dual role of SLC35F2 in brain health and tumor biology rests on cell-culture and animal-model evidence rather than human outcome data.
Another unresolved issue is redundancy. Many solute carrier family members transport overlapping sets of molecules. The current data argue that SLC35F2 is the dominant queuine importer, but they do not fully exclude the possibility that other transporters partly compensate in some tissues. Disentangling that redundancy will require tissue-specific knockouts in animal models and careful measurement of queuosine levels in tRNA from different organs.
Finally, the translational path will hinge on safety. Any drug that blocks SLC35F2 must be tested for subtle cognitive or developmental effects, particularly if given to children or older adults whose brains may be more sensitive to disruptions in tRNA modification. Conversely, agents that boost queuine uptake will need to be evaluated for unintended support of malignant cells that overexpress SLC35F2. Balancing those risks and benefits will demand close collaboration between basic scientists, oncologists, neurologists and nutrition researchers.
For now, the identification of SLC35F2 as the queuine transporter transforms a long-standing biochemical puzzle into a tractable medical question. It turns an abstract dependency on a mysterious micronutrient into a specific protein that can be measured, modulated and, eventually, targeted in the clinic. As researchers fill in the remaining gaps-from diet and microbiome influences to genetic variation and tissue maps-the queuine transporter may evolve from a curiosity of RNA chemistry into a practical lever for protecting the brain and disarming cancer.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
